Search research articles
Contact Us
Filters
Showing results (201-210 of 242) with videos related to
Page
of 25
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 5, 2014
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry
C Medina, G Carretero, C Ferrandiz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 23, 2016
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
P Dávila-Seijo, E Dauden, G Carretero, et al.
Expert Opinion on Biological Therapy
|
December 18, 2023
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study
A Chiricozzi, S M Ferrucci, L Di Nardo, et al.
International Journal of Dermatology
|
May 13, 2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group
Antonio Sahuquillo-Torralba, Miguel Mansilla-Polo, Conrad Pujol-Marco, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
March 31, 2023
Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain
Alexandre Docampo-Simón, María J Sánchez-Pujol, Maria A Pastor-Nieto, et al.
Actas Dermo-Sifiliograficas
|
May 24, 2014
Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles)
M Sánchez-Regaña, M J Aldunce Soto, I Belinchón Romero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 3, 2017
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
A Pérez-Plaza, G Carretero, C Ferrandiz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 16, 2013
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
J M Carrascosa, M Vilavella, I Garcia-Doval, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 10, 2017
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
I Belinchón, J M Ramos, G Carretero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 10, 2020
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
E Del Alcázar, J A Suárez-Pérez, S Armesto, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 242) with videos related to
Sort By:
Page
of 25
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 5, 2014
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry
C Medina, G Carretero, C Ferrandiz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 23, 2016
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
P Dávila-Seijo, E Dauden, G Carretero, et al.
Expert Opinion on Biological Therapy
|
December 18, 2023
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study
A Chiricozzi, S M Ferrucci, L Di Nardo, et al.
International Journal of Dermatology
|
May 13, 2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group
Antonio Sahuquillo-Torralba, Miguel Mansilla-Polo, Conrad Pujol-Marco, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
March 31, 2023
Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain
Alexandre Docampo-Simón, María J Sánchez-Pujol, Maria A Pastor-Nieto, et al.
Actas Dermo-Sifiliograficas
|
May 24, 2014
Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles)
M Sánchez-Regaña, M J Aldunce Soto, I Belinchón Romero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 3, 2017
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
A Pérez-Plaza, G Carretero, C Ferrandiz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 16, 2013
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
J M Carrascosa, M Vilavella, I Garcia-Doval, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 10, 2017
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
I Belinchón, J M Ramos, G Carretero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 10, 2020
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
E Del Alcázar, J A Suárez-Pérez, S Armesto, et al.
Page
of 25